Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin renal oxygenation study in type 2 diabetes with or without diabetic kidney disease
ChiCTR1900025788Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of empagliflozin and linagliptin in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Huashan Hospital. Primary endpoint: Kidney oxygenation index. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
empagliflozinlinagliptin
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1900025788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025788.